ImmunoCellular Therapeutics, Ltd. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. Net loss for the quarter ended September 30, 2017, was $3.9 million compared to $4.8 million in the same period in 2016. Net loss available to common shareholders for the quarter ended September 30, 2017, was $6.1 million, or $0.40 per basic and diluted common share, compared to $4.8 million, or $1.58 per basic and diluted common share, in the same period in 2016. The 2017 net loss available to common shareholders includes the net loss of $3.9 million plus $1.6 million of deemed dividends and $600,000 of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. Loss before other income was $3,900,988 against $5,472,276 a year ago. Interest income was $109 against $9,920 a year ago. For the nine months ended September 30, 2017, the company incurred a net loss of $13.9 million compared to $15.8 million in the same period in 2016. Net loss available to common shareholders for the nine months ended September 30, 2017 was $16.1 million, or $2.13 per basic and diluted share, compared to $15.8 million, or $6.19 per basic and diluted share, during the same period in 2016. The 2017 net loss available to common shareholders includes the net loss of $13.9 million plus $1.6 million of deemed dividends and $600,000 of original issue discount associated with the convertible preferred stock issued as part of the July 2017 financing. The company used $11.7 million of cash in operations compared to $16.1 million in the same period in 2016. Loss before other income was $20,721,753 against $16,792,720 a year ago. Interest income was $4,284 against $18,831 a year ago.